Research / Testosterone & Cardiovascular Risk / Article

Testosterone replacement therapy and cardiovascular disease.

International journal of impotence researchNovember 2022PMID 34999717DOI 10.1038/s41443-021-00516-6

Jeremy M Auerbach, Mohit Khera

Journal ArticleReviewTestosterone & Cardiovascular Risk

MODERATE

Evidence strength

Derived from study design, sample signals, and bias cues in available metadata — not a mystery score.

HIGH

Clinical relevance

How directly the endpoints and population map to hormone-medicine practice.

MODERATE

Risk / caveats

Lower meter values mean higher remaining bias or confounding concern.

Key takeaway

Testosterone therapy should be individualized with cardiovascular risk assessment and monitoring rather than categorically avoided.

Study at a glance

Design

Journal Article

Journal / year

International journal of impotence research · November 2022

Population

Humans

Endpoint

Testosterone therapy should be individualized with cardiovascular risk assessmen

Abstract

The use of testosterone therapy has a complex history of apprehension and questions regarding its safety. Despite an eventual consensus that testosterone therapy was safe and effective, several studies relating to cardiovascular risks emerged in the last decade, rekindling skepticism regarding the safety of testosterone therapy. Given the utility of testosterone therapy in treating the symptoms of hypogonadism, it remains crucial to closely examine the safety of testosterone therapy. The present article synthesizes the current evidence regarding cardiovascular risks that may be associated with testosterone therapy, the potential mechanisms regarding testosterone's efficacy, and future directions in evaluating the safety of its use.